A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors

NCT06656390 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

202

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancer
Advanced Solid Tumors

Interventions

DRUG: ALK201

Sponsor

Shanghai Allink Biotherapeutics Co., Ltd.